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Introduction: The Epithelial Cell Adhesion Molecule (EpCAM) has been shown to be strongly expressed in human
breast cancer and cancer stem cells and its overexpression has been supposed to support tumor progression and
metastasis. However, effects of EpCAM overexpression on normal breast epithelial cells have never been studied
before. Therefore, we analyzed effects of transient adenoviral overexpression of EpCAM on proliferation, migration
and differentiation of primary human mammary epithelial cells (HMECs).
Methods: HMECs were transfected by an adenoviral system for transient overexpression of EpCAM. Thereafter,
changes in cell proliferation and migration were studied using a real time measurement system. Target gene
expression was evaluated by transcriptome analysis in proliferating and polarized HMEC cultures. A Chicken
Chorioallantoic Membrane (CAM) xenograft model was used to study effects on in vivo growth of HMECs.
Results: EpCAM overexpression in HMECs did not significantly alter gene expression profile of proliferating or
growth arrested cells. Proliferating HMECs displayed predominantly glycosylated EpCAM isoforms and were
inhibited in cell proliferation and migration by upregulation of p27KIP1 and p53. HMECs with overexpression of
EpCAM showed a down regulation of E-cadherin. Moreover, cells were more resistant to TGF-β1 induced growth
arrest and maintained longer capacities to proliferate in vitro. EpCAM overexpressing HMECs xenografts in chicken
embryos showed hyperplastic growth, lack of lumen formation and increased infiltrates of the chicken leukocytes.
Conclusions: EpCAM revealed oncogenic features in normal human breast cells by inducing resistance to
TGF-β1-mediated growth arrest and supporting a cell phenotype with longer proliferative capacities in vitro. EpCAM
overexpression resulted in hyperplastic growth in vivo. Thus, we suggest that EpCAM acts as a prosurvival factor
counteracting terminal differentiation processes in normal mammary glands.
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EpCAM (also known as 17-1A, GA733-2, KSA, ESA,
and EGP-40) is a homophilic, calcium-independent cell
adhesion molecule of 39–42 kDa [1,2] expressed on most
normal and cancerous epithelial tissues, cancer stem cells,
embryonic stem cells and germ cells [3-5]. EpCAM is a type
I transmembrane glycoprotein encoded by the TACSTD1
gene. The EpCAM protein contains an extracellular domain* Correspondence: Gerold.Untergasser@i-med.ac.at
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distribution, and reproduction in any medium(EpEX) with a nidogen-like domain as well as thyroglobulin-
and epidermal growth factor-like repeats, a single transmem-
brane region, and a short intracellular domain (EpICD)
consisting of 26 amino acids. EpCAM has been shown to
be expressed on normal epithelial cells in situ at intercel-
lular basolateral interfaces [1]. In regard to its function, it
has been shown in the developing zebrafish, that EpCAM-
lacking mutants display defects both in epithelial morpho-
genesis and epithelial integrity [1,6]. Moreover, mutants
show abnormal skin development with higher infection
susceptibility and enhanced skin inflammation [1,6]. In
regard to mammals, EpCAM−/− mice die in uterus attral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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play prominent placental abnormalities [7].
In tumor development and progression EpCAM has a
controversial biological role [5]. As an adhesion mol-
ecule, EpCAM mediates homophilic cell-cell adhesion
interactions thereby preventing metastasis [1,2]. In colo-
rectal cancer EpCAM appears to act as molecule with
protective function, since EpCAM deletions result in a
higher risk to develop cancer [8] and overexpression of
EpCAM in colorectal cancer cells has been shown to in-
hibit metastasis and invasion of tumor xenografts in
mice [9].
On the other hand, it is known that EpCAM can abro-
gate E-cadherin mediated cell-cell adhesion thereby pro-
moting metastasis [10]. Furthermore, it has been shown
that EpCAM overexpression in cancer cells can support
proliferation by enhancing Wnt signaling [11]. In breast
carcinoma patients, high EpCAM expression was ob-
served in less differentiated tumors [12] and was associ-
ated with larger tumors, nodal metastasis and worse
survival of patients [13]. Moreover, high EpCAM expres-
sion correlated with poor prognosis in both node positive
and node negative disease [14]. Due to its high expression
in breast cancer tissue, EpCAM has emerged as an attract-
ive target for treatment of breast cancer patients and re-
cent studies with the humanized EpCAM antibody
Adecatumumab showed already promising results in pa-
tients with EpCAM overexpression [15]. Moreover, the
approval by the European Union in 2009 of the EpCAM-
specific antibody Catumaxomab, adds a therapeutic option
also in breast cancer patients with peritoneal carcinoma-
tosis and malignant ascites [16].
Although it has been shown that EpCAM is expressed
in normal epithelial cells [17] the role in normal breast
tissue homeostasis is still unclear. In this study we ana-
lyzed effects of adenoviral overexpression of EpCAM on
growth, migration and differentiation of normal breast
epithelial cells. Moreover, we screened for genes altered
by overexpression of EpCAM in normal epithelial cells
of the breast and analyzed in vivo growth in a chicken
xenograft model.Material and methods
Tissue samples
A Human Breast Cancer Tissue Array, with matched
metastatic carcinoma tissue (BR10010-2-BX), including
TNM and pathology grade (50 cases, 100 cores) was
purchased from Biocat and was composed of primary
breast carcinoma (n = 50) with corresponding lymph
node metastasis (n = 50). Samples from normal breast
tissue (n = 5) were obtained in form of paraffin-embed-
ded tissue block slides with normal breast tissue (Breast
T2234086-BC). Detailed information about all tumorsamples can be found on the supplier’s web site (http://
www.biocat.com)
Primary cell cultures (HMECs)
Human Mammary Epithelial Cells (HMECs, n = 4) were
purchased from Promocell. HMECs were cultivated in
Mammary Epithelial Cell Growth Medium with
recommended supplements (Promocell, 0.004 mL/mL Bo-
vine Pituitary Extract, 10 ng/mL Epidermal Growth Factor,
5 μg/mL Insulin and 0.5 μg/mL Hydrocortisone) on colla-
gen-type-I (Sigma Biochemicals) coated ventilated plastic
flasks. Cells were passaged by collagenase-type-I treatment
(1 mg/mL, Sigma Biochemicals) and a cell detach kit
(Promocell) consisting of 30 mM Hepes, 0.04%/0.03%
Trypsin/EDTA Solution and Trypsin Neutralizing Solu-
tion (TNS). For TGF-β1 induced differention experiments
cells were stimulated for 72 h with 1 ng/mL TGF-β1 re-
combinant human TGF-β1 R&D Systems in growth factor
reduced medium. Cell numbers were determined 3 and
6 days after transfection and TGF-β1 stimulation by try-
pan-blue staining (Invitrogen) in the Buerker Tuerk
counting chamber.
MCF-10A cell line
Immortalized non-tumorigenic human mammary epi-
thelial cells (MCF-10A) were obtained from the ATCC
and cultivated in Dulbecco’s modified Eagle’s medium
F12 (DMEM/F12) supplemented with 5% horse serum
(both Invitrogen), 1% penicillin/streptomycin (PAA La-
boratories GmbH), 0.5 μg/mL hydrocortisone, 10 μg/mL
insulin and 20 ng/mL recombinant human EGF (all from
Sigma Biochemicals).
MCF-10Ans/ctrl and MCF-10AE#2 (control and EpCAM
knockdown by shRNA) cell lines were generated by trans-
fection with pGIPZ-shRNA-mir lentivirus as described
elsewhere [18] and selected with 3 μg/mL puromycin
(Invitrogen) for 5 days in standard culture medium.
Generation of polarized cultures of HMECs
HMECs of 3 independent donors were seeded on a
transwell 0.4 μm polyester membrane (Costar) coated
with growth factor reduced matrigel (BD Biosciences,
50 μg/cm2). Cell culture medium was exchanged daily.
Until day 4–5 cells formed confluent monolayer and
until day 12 they polarized. The polarization status of
the culture was confirmed by transepithelial resistance
measurement using the STX2 electrode and the EVOM
epithelial voltohmmeter (World Precision Instruments,
WPI). For transepithelial resistance calculations we used the
following formule: (measured value – blank value) × 18.1.
Immunohistochemistry
Tissue sections were deparaffinized and hydrated in xylene
and graded alcohol series. Antigen retrieval was performed
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solution (Dako Cytomation) and endogenous peroxidase
activity was blocked with 3% H2O2/methanol. Sections were
incubated in blocking solution containing 10% bovine calf
serum (Dako Cytomation) for 45 min and then stained for
one hour with primary antibody (mouse anti-human
EpCAM, ESA, clone VU-1D9, Novocastra, 1 μg/mL).
Moreover, serial sections were incubated with a monoclonal
mouse anti-human cytokeratin high molecular weight (clone
34ßE12; 1:100, Dako Cytomation), anti human cytokeratin
18 (clone DC-10; 1:50, Dako Cytomation), alpha smooth
muscle cell actin (clone 1A4; 1:100, Sigma Biochemicals)
and anti human p63 (clone 4A4; 1:50, Dako Cytomation).
Primary antiserum was detected after incubation with a
biotinylated secondary antibody (biotinylated rabbit anti-
mouse IgG, Vector Laboratories Inc.) using the Vectastain
Elite ABC Kit (Vector Laboratories Inc.) and the FAST
DAB Tablet Set (Sigma Biochemicals). Sections were
counterstained with Meyer’s hematoxylin and mounted
with Pertex (Medite).
Immunofluorescence
Cells were seeded on a Matrigel coated eight-well cul-
ture slides (Falcon BD Labware). Polarized 3D cultures
cells were fixed, permeabilized and stained directly on
Matrigel coated transwells. After being fixed in 4% para-
formaldehyde and permeabilized with 0.2% Triton-X-100
cells were blocked with PBS containing 3% BSA for
45 min at room temperature (RT). All antibodies of the
immunohistochemistry section and additional antibodies –
anti human ZO-1 (clone 1/ZO-1, BD Biosciences
Pharmingen), anti human E-cadherin (clone 32A8,
Cell Signaling Technology), anti-β-catenin (clone 14/
Beta-Catenin, BD Biosciences Pharmingen) were ap-
plied in a 1:100 dilution at RT for two hours. After
washing in PBS cells were incubated with secondary
fluorochrome-labeled antibodies (FITC-labeled/PE-la-
beled rabbit anti mouse, Dako Cytomation) and nuclei
were counterstained with TO-PRO-3 Iodide or DAPI
(both Molecular Probes). Cells were embedded in fluores-
cent mounting medium (Dako Cytomation) and viewed
by a Fluorescence Microscope (Zeiss Axiovert 200, Carl
Zeiss, Axiovision Software).
Western blot analysis
Cells were harvested and lysed in a RIPA buffer (Sigma
Biochemicals) containing protease inhibitors (Complete
Mini EDTA-free; Roche Applied Science). 20 μg total
protein was denaturated, separated by a 4-20% SDS-
PAGE (Criterion TGX, Bio-Rad) and transferred to
Immuno-Blot™ polyvinylidene difluoride (PVDF) mem-
brane (Bio-Rad). After blocking the membrane in 5% non-
fat milk powder dissolved in phosphate-buffered saline
(PBS), membranes were incubated in 1% non-fat milkpowder at 4°C overnight with primary mouse antibodies.
Afterwards, membranes were incubated with a HRP-con-
jugated goat anti-mouse IgG (Dako Cytomation) diluted
1:1000. After washing, a chemoluminescent substrate
(LumiGLO Reagent and Peroxide, Cell Signaling Technol-
ogy) was added to the membrane, which was then exposed
in the Chemidoc XRS station (Biorad Laboratories). Anti-
bodies used for Western analysis were C-10 (mouse mono-
clonal against human EpCAM, Santa Cruz Biotechnology),
alpha tubulin (clone B5-1-2; Sigma Biochemicals), E-cadherin
(clone 32A8, Cell Signaling Technology), Vimentin (clone v9,
Dako Cytomation), Cytokeratin 18 (clone DC 10, Dako),
Cytokeratin, High Molecular Weight (clone 34ßE12, Dako
Cytomation), p27Kip1 (clone G173-524, BD Pharmingen) and
p53 (clone PAb1801, Calbiochem).
PNGaseF treatment
Enzymatic deglycosylation of total protein (20 μg) was
performed with PNGaseF enzyme (New England
Biolabs) according to manufacturer’s protocol. There-
after, protein extracts were analyzed by Western Blot.Adenoviral overexpression of EpCAM
Replication-defective adenoviruses were generated with the
Ad-Easy Adenoviral vector system (Stratagene) according
to the manufacturer’s instructions and as described else-
where [19]. In brief, the EpCAM cDNA (NM_002354,
Openbiosystems) was subcloned into the pShuttle CMV
GFP vector and sequenced. Recombinant adenoviral DNA
was generated in BJ5183 bacteria cells using a double-re-
combination event between cotransfected adenoviral back-
bone plasmid vector, pAdEasy-1, and a shuttle vector
carrying the gene of interest. For generation of replication-
defective adenovirus recombinant DNA was transfected
into HEK293 cells using Lipofectamin 2000 (Invitrogen).
All viral titers were determined by qPCR for the gene cod-
ing for the encapsulation signal (for:5-cgacggatgtggcaaaagt,
rev: 5-cctaaaaccgcgcgaaaa) and the respective viral plasmid
DNA standards. HMECs were transfected with a multipli-
city of infection (MOI) of 100 viruses/cell and tested for
gene and protein expression 24 to 118 hours after transfec-
tion. All cell proliferation, migration and in vivo assays were
performed at least 24 hours after adenoviral transfection to
allow efficient EpCAM overexpression.Flow cytometry
For FACS analysis of membranous EpCAM staining,
cells were washed in PBS, resuspended and incubated
with the first anti-EpCAM antibody (sc-25308, Santa
Cruz Biotechnology, 1 μg/mL) for 30 min and then with
the second, PE-labeled antibody (PE-labeled rabbit anti
mouse, Dako Cytomation). Thereafter, cells were washed
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FACSCalibur (Becton-Dickinson, Heidelberg, Germany).
HMEC cell death was evaluated by human APC-la-
belled Annexin V (Alexis Biochemicals) and propidium
iodide (PI, Sigma Biochemicals) stainings. Cells were
adenovirally transfected (MOI = 100) and incubated for
24 hours. Thereafter, cells were resuspended in 200 μl
Annexin V Binding Buffer (abcam) with 5 μL of Annexin
V and 2 μL of PI (20 μg/mL), incubated for 15 minutes
on ice, washed and resuspended in PBS/5% FCS prior
the analysis. Cells were examined in the FACSCalibur
(Becton-Dickinson, Heidelberg, Germany).Microarray data set generation and analysis
Gene expression profiling analysis was performed at the
Expression Profiling Unit of the Medical University
Innsbruck. RNA quantity was determined by optical
density measurements and RNA integrity using the 2100
Bioanalyzer (Agilent Technologies, Palo Alto, CA). Fifty
ng high quality RNA were processed using the WT Ex-
pression Kit (Ambion) and the WT Terminal Labeling
Kit (Affymetrix). The resulting biotinylated targets
were hybridized to Affymetrix Human Gene ST 1.0 v
microarrays. Microarrays were washed and stained in
an Affymetrix fluidic station 450, fluorescence signals
were recorded by an Affymetrix scanner 3000 and
image analysis was performed with the GCOS software
(Affymetrix). Raw and preprocessed microarray data have
been deposited at the Gene Expression Omnibus accession




Total RNA was isolated from HMECs using the
TriReagent (Sigma Biochemicals), according to manufac-
turer’s instructions. For microarrays, RNA was purified by
cell lysis and nucleic acid extraction using the RNeasy Kit
(Qiagen). Thereafter, viral and genomic DNA in the RNA
samples was digested with the RQ1 DNAse (Promega).
The cDNA was amplified from 1 μg total RNA by the use
of the SuperScript II Reverse Transcriptase Kit (Invitrogen
Life Technologies). For validation, real time RT-PCR was
performed using a SensiMix SYBR No-ROX Kit (Bioline)
and a Rotor-Gene 6000 detection system (Corbett
Research). Primers were designed to amplify specific
GAPDH (for: 5-CTGACCTGCCGTCTAGAAAA; rev: 5-
GAGCTTGACAAA GTGGTCGT), TATA Box Binding
Protein (for: 5-GGAGCCAAGAGTGAAGAACA; rev: 5-
AGCACAAGGCCTTCTAACCT) and EpCAM (for: 5-
GCTGGTGTGTGAACACTGCT; rev: 5-ACGCGTTGT
GATCTCCTTCT).Real time cell proliferation and migration assay
(xCelligence system)
Real time cell proliferation and migration experiments
were performed using the RTCA DP instrument (Roche
Diagnostics GmbH), which was placed in a humidified in-
cubator maintained at a 5% CO2 at 37°C. For proliferation
assay cells were seeded in complete medium in 16-well
plates (E-plate 16, Roche Diagnostics GmbH) at density of
5,000 cells/well. The plate containing gold microelectrodes
on its bottom was monitored every 10 minutes for 4 hours
(adhesion process), then once every 30 min, until the end
of experiment, which was in total 72 hours (cell prolifera-
tion). Cell migration was performed using special 16-well
plates with 8 μm pores (CIM-plate 16, Roche Diagnostics
GmbH). These plates, resembling conventional transwells,
have microelectrodes placed on the underside of the
membrane. Cells were seeded into the upper chamber at a
density of 20,000 cells/well in a serum free medium and
the lower chamber was filled with complete medium. The
plate was monitored every 15 minutes for 12 hours. Data
analysis was performed using RTCA software 1.2 supplied
with the instrument.
Senescence associated-beta galactosidase (SA-β-gal)
activity assay
Cells were fixed (2% formaldehyde, 0.2% glutaraldehyde in
PBS) for 5 min at room temperature and rinsed several
times in PBS. To measure SA-β-gal activity, cells were in-
cubated in a staining-solution (4.2 mM citric acid,
12.5 mM sodium-phosphate, 158 mM sodium chloride,
0.21 mM magnesium chloride, 2.21 mg/mL potassium
ferrocyanid, 1.68 mg/mL potassium ferricyanid, 1 mg/ml
X-Gal, pH 6.0) for 24 h at 37°C. Cells were washed and
embedded in PBS, viewed in an inverted transmission-
microscope and photographed (Zeiss Axiovert 200,
Axiovision software).
Chicken chorioallantoic membrane (CAM) xenograft
model
On embryo development day 0 fertilized chicken eggs
(Gallus domesticus, Charles River) were placed in a 75-80%
humidified 37°C incubator (Grumbach) to allow normal
embryo development. On day 3 eggs were opened, egg
shells removed and embryos were placed in a sterile Petri
dish in an egg incubator to induce CAM development. On
day 8, when chorioallantoic membrane (CAM) and its
vasculature were well developed, all experiments were
performed. HMECs were transfected one day before the ex-
periment either by EpCAM adenoviruses or GFP control
adenoviruses (both MOI = 100). 3.0 × 105 cells were resus-
pended in a 30 μL drop of ice-cold growth-factor reduced
Matrigel (Becton Dickinson) containing TGF-β1 in a con-
centration of 1.7 ng/mL and the mixture solidified for








A                             B
EpCAM
Figure 1 Characterization of primary human mammary
epithelial cells (HMECs). Paraffin sections (A) or HMECs cultivated
on collagen-coated cover slides (B) were stained with antibodies
(markers) specific for myoepithelial (ASMA), basal/stem cells (p63),
basal cells (CK5/14), and luminal cells (CK18). Immunohistochemical
stainings revealed that in vivo EpCAM was expressed in basal and
luminal cells of the breast, but not in myoepithelial cells.
Immunofluorescence analysis revealed that HMECs stain for basal
marker CK5/14, but were consistent negative for EpCAM, p63 and
ASMA (n = 3). Magnification 200 ×; bars indicate 50 μm.
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inspected on a daily basis using a stereo fluorescence
microscope (Olympus SZW 10). On day 6 post-grafting
chicken embryos were sacrificed with hypothermia, xeno-
grafts cut out and stored either in 4% paraformaldehyde for
immunohistochemical studies or in TRI-reagent (Sigma
Biochemicals) for RNA isolation.
Statistical analyses
Statistical analyses were performed with the GraphPad
Prism™ 5.0 (GraphPad Software, Inc.) software for
Windows. All tests of statistical significance were two-
sided. Student’s T test, two-way ANOVA and Mann–
Whitney U Tests were used to study differences between
two groups. Statistical analyses of quantitative PCR data
were performed according to the delta Ct method de-
scribed by Pfaffl et al. [20] and p values were calculated
with the Student’s T Test. Data analysis of microarrays
was performed in R (http://www.r-project.org) using
packages from the Bioconductor project. The custom
Ensembl transcript based CDF package (v13) from the
brainarray group was used for probe set definitions.
GeneChip raw expression values were preprocessed
using the RMA method. After preprocessing a represen-
tative transcript probe, the set was selected for each gene
as described previously [21]. In brief, a combination of
average and variation of expression of a probe set across
all samples was used to select the most informative tran-
script probe set for a gene. The moderated t-test was
employed to assess significance of differential expression
of a probe set between EpCAM overexpressing and con-
trol samples. The resulting raw p-values were adjusted
for multiple hypotheses testing with Benjamini and
Hochberg’s method for a strong control of the false
discovery rate. Raw and preprocessed microarray data
have been deposited at the Gene Expression Omnibus
(accession number GSE37172, GSE39071).
Results
Expression of EpCAM in normal breast tissue and primary
human mammary epithelial cells
In the mammary gland all epithelial cells express EpCAM
with the exception of myoepithelial cells. There were no
significant changes in immunoreactivity between luminal
and basal cells (Figure 1A). In clear contrast to all tumor
samples analyzed, normal polarized epithelia had a strict
localization of EpCAM on the basolateral membrane. This
basolateral expression got lost in tumor cells of primary
breast carcinoma and metastasis which showed clearly
localization on the entire cell surface (Additional file 1:
Figure S1). Primary epithelial cells from healthy breast tis-
sue (HMECs) were analyzed for their phenotype by a
panel of markers specific for myoepithelial (ASMA),
progenitor (p63), basal (CK5/14) and luminal (CK18)epithelial cells. As expected, all HMECs lacked luminal
(CK18-) or myoepithelial (ASMA-) markers, but displayed
more a basal phenotype (p63-, CK5/14+). Interestingly,
in vitro cultivated HMECs were negative for EpCAM in
the immunofluorescence analysis (Figure 1B), although
low transcript levels could be detected by qPCR analysis
(data not shown).
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proliferation and migration in HMECs
Based on our observations that HMECs display low en-
dogenous EpCAM expression in 2-dimensional cultures,
we overexpressed the putative EpCAM oncogene and ana-
lyzed effects on cell proliferation and migration in vitro.
Using a multiplicity of infection (MOI) of 100 viruses/
cell we obtained a strong EpCAM expression in HMECs
(Figure 2A) without any effects on cell viability (Additional








































Figure 2 Adenoviral overexpression of EpCAM in HMECs inhibits cell
transfected to overexpress EpCAM and GFP or GFP alone. A multiplicity of
Overexpression of EpCAM was confirmed 48 h after transfection by Immun
cytoplasm (Phycoerythrin, red signal). Nuclei were counterstained with DAP
overexpression was analyzed by real time PCR using GAPDH as housekeep
expected, overexpression resulted in a more than hundred-fold induction o
expression was confirmed by Western Blot analysis (C). In comparison to co
proliferating cells and primarily as not glycosylated isoform in growth arres
deglycosylation experiments with PNGaseF and subsequent Western Blot a
glycosylated isoforms to the 35 kDa not glycosylated EpCAM isoform (D). C
system. EpCAM overexpression significantly inhibited cell proliferation (E). W
overexpression; p53 and p27KIP1 proteins were upregulated in EpCAM over
plate system after adenoviral transfection of EpCAM or GFP (G). EpCAM oveprotein on plasma membrane (Additional file 2: Figure
S2A) we found a lot of immunoreactive EpCAM in cyto-
plasmic organelles in our immunofluorescence analysis
(Additional file 1: Figure S1D). These high amounts of
cytoplasmic EpCAM might originate by overload of the
intracellular vesicular traffic system with EpCAM or by a
preferential detection of cytoplasmic EpCAM isoforms in
our immunofuorescence analysis.
A transient, about hundred-fold overexpression was


























































proliferation and migration. HMECs (n = 3) were adenovirally
infection of 100 viruses/cell was used for all experiments.
ofluorescence (A). EpCAM was expressed on cell surface and
I (blue signal, magnification 400×, bars indicate 25 μm). EpCAM
ing gene for normalization and GFP transfected cells as controls (B). As
f EpCAM gene expression even 5 days after transfection. Protein
ntrol cells EpCAM was overexpressed as glycosylated isoform in
ted HMECs. EpCAM glycosylation has been analyzed by enzymatic
nalysis. In all samples we observed a reduction of the 40-42 kDa
ell proliferation was analyzed in real time by the use the xCelligence
estern Blot analysis of cell cycle inhibition 48 h after EpCAM
expressing cells. (F). Cell migration was monitored by xCelligence CIM
rexpression also inhibited cell migration; stars indicate p values < 0.05.
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HMECs was also confirmed on protein level by Western
Blot analysis (Figure 2C). Interestingly, proliferating
HMECs produced predominantly glycosylated isoforms
(days 1 to 3), whereas in confluent and contact-inhibited
cultures most of EpCAM protein was not glycosylated
(Figure 2C). The presence of different EpCAM isoforms
in HMECs was confirmed by enzymatic deglycosylation
experiments with the enzyme PNGaseF and subsequent

























































Figure 3 Analysis of EpCAM target genes in HMECs. HMECs were cultiv
coated transwells to induce polarization of epithelial monolayers (B). Then,
alone or EpCAM/GFP. Polarized HMECs cells did not express immunoreactiv
β-catenin as determined by Immunofluorescence analysis (C, bars indicate
(HMEC 1–3) were adenovirally transfected and EpCAM gene expression qu
keeping gene (D). MA-plot of genes regulated by EpCAM as determined b
polarized cultures of HMECs (F). Besides EpCAM no additional genes were
transfection. Mean M-values indicate differential gene expression between EpC
indicate average expression of a gene in all microarrays. Stars indicate p valuesstimulation EpCAM overexpression inhibited cell growth
in proliferating HMECs as determined by the Real Time
Cell Proliferation System (Figure 2E). In comparison to
control cells, EpCAM transfected cells showed elevated
expression of the tumor suppressor genes, p27Kip1 and p53
(Figure 2F). However, these changes were visible only as a
post-transcriptional regulation, on the protein level. Gene
expression levels of TP53 and p27Kip1 did not significantly
change after adenoviral transfection (Additionl file 2: Figure















ated as mitotic subconfluent cultures (A) or for 10 days on Matrigel-
cells were adenovirally transfected (MOI = 100) to overexpress GFP
e EpCAM protein, but the gap junction protein ZO-1, E-cadherin and
25 μm). Polarized cells and mitotic cultures (log-phase) of three donors
antified 24 h later by real time PCR using GAPDH as internal house-
y Affymetrix Gene analysis in mitotic standard cultures (E) or confluent
significantly regulated in all three donors analyzed 20 h after
AM over-expressing and GFP transfected cells (log2 scale), Mean A-values
<0.05.
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real time cell migration measurement (Figure 2G).
EpCAM expression is not induced by polarization
processes in HMECs
Although EpCAM expression was strictly basolateral in
breast epithelia in vivo, it was not expressed in our in vitro
cultures of HMECs (Figure 1B). Therefore, we concluded,
that maintenance of cell polarity with functional tight- and
gap- junctions is necessary for the expression of EpCAM
and for further overexpression studies. HMECs were
grown as mitotic cultures on collagen type I (Figure 3A)
or as confluent, polarized monolayers on 0.4 μM transwell
inserts coated with Matrigel (Figure 3B). Polarization of
HMECs was controlled after 10 days by measurement of
transepithelial resistance (860 ±50Ω) and by immuno-
fluorescence stainings for the tight junction marker ZO-1,
and cell-cell contacts mediated by E-cadherin and mem-
branous β-catenin. Cell-cell contact proteins E-cadherin
and β-catenin, molecular interaction partners of EpCAM,
were strongly expressed in polarized HMECs cultures
(Figure 3C). However, we could not observe elevated
EpCAM protein expression (Figure 3C).
EpCAM overexpression does not alter gene expression
profile of HMECs
HMECs grown as polarized cultures or under mitotic
culture conditions were adenovirally transfected to
overexpress EpCAM/GFP or GFP. As expected, transi-
ent transfection resulted in a strong overexpression of
EpCAM in comparison to control cells (Figure 3D). Des-
pite equal multiplicities of infection (MOI = 100) used
for all transfections, EpCAM overexpression was stron-
ger in polarized cells than in standard culture condi-
tions. Based on our data on EpCAM protein expression
(Figure 2C) we isolated mRNA 24 h after adenoviral
transfection to identify genes directly regulated by
EpCAM and not thereafter, by induction of the tran-
scription factor p53. Apart from the clear overexpression
of EpCAM, we did not observe any significant changes
in the gene expression profile of HMECs under normal
and polarized culture conditions (Figure 3E/F, Additional
file 3: Table S1). These microarray data indicate that
EpCAM overexpression alone does not directly affect
gene transcription in HMECs either cultured in a polar-
ized, tissue resembling culture model or under mitotic
standard conditions.
EpCAM antagonizes TGF-β1 induced growth arrest
TGF-β1 acts on epithelial cells as potent growth inhibitory
factor and promotes differentiation processes. Basal cells
stimulated with TGF-β1 stop proliferation within 3 days. In
contrast to untreated control cells, displaying a small cell
body and a strong light refracting morphology, TGF-β1treated cells changed morphology and acquired an enlarged
and flat cell body (Figure 4A/B, green signal). After EpCAM
overexpression, TGF-β1 stimulated HMECs showed a
higher percentage of cells with a small, strongly light-ref-
racting morphology (Figure 4A, arrows). Moreover, HMECs
treated with TGF-β1 underwent a terminal growth arrest
and stained positively for senescence-associated beta galac-
tosidase (SA-β-Gal; Figure 4B), a marker of cellular sene-
scence. In clear contrast, upon simultaneously EpCAM
overexpression, we could observe many cell clusters that
were negative for SA-β-Gal (Figure 4B, arrows) indicating
that cells were not growth arrested and maintained a longer
capacity to proliferate.
EpCAM down regulates E-cadherin and prolongs
proliferative lifespan of HMECs
Long term cultures of HMECs in culture medium
containing TGF-β1 were analyzed for differences between
EpCAM/GFP and GFP overexpression. In the presence of
the differentiation factor TGF-β1 EpCAM overexpressing
cells were still able to proliferate and formed bigger cell
clusters after 6 days in vitro (Figure 4C). GFP transfected
control cells stopped cell divisions after 3 days and con-
sisted predominantly of enlarged, flat and growth arrested
cells (Figure 4C). Analysis of cell numbers revealed a signifi-
cant increase in cell counts in EpCAM overexpressing cells
6 days after transfection (Figure 4D).
Additionally, we analyzed a panel of epithelial-to-mesen-
chymal transition (EMT) markers to define the phenotype
of EpCAM overexpressing cells. In particular, HMECs
showed down regulation of E-cadherin after TGF-β1
stimulation (Figure 4E, 4F). In clear contrast to GFP con-
trol cells, EpCAM-overexpressing cells showed an add-
itional down regulation of E-cadherin (Figure 4E, 4F),
which would explain the more spindle-shape phenotype of
the cells (Figure 4A). Another marker of EMT, vimentin
expression, did not increase significantly after EpCAM
overexpression in direct comparison to GFP transfected
control cells (Figure 4E, 4F).
EpCAM overexpressing HMECs form bigger xenografts
consisting of p63high progenitor cells and lack luminal
structure formation
Based on in vitro findings we analyzed effects of EpCAM
overexpression in our in vivo model. Therefore, we
transplanted HMEC xenografts onto chicken embryos to
analyze in vivo growth (Figure 5A). Chicken embryos have
only innate immune responses and thus, tolerate growth
of human cells. Transfected HMECs were transplanted as
growth factor-reduced matrigel drops containing TGF-β1.
After 6 days in vivo growth, xenografts became well
vascularized and human onplants could be visualized by
expression of GFP (Figure 5B). Macroscopically, there
were no significant changes in the size of HMEC onplants,















































































Figure 4 (See legend on next page.)
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Figure 4 EpCAM inhibits TGF-β1 induced terminal growth arrest and differentiation in HMECs. Adenovirally transfected HMECs were
stimulated with 1 ng/mL TGF-β1 to undergo terminal growth arrest and differentiation in vitro. (A) In comparison to control cells TGF-β1 treated
GFP expressing cells got growth arrested, flat and enlarged. Populations of EpCAM transfected cells were protected from TGF-β1 and acquired a
small cell body (white arrows). (B) In comparison to proliferating control cells TGF-β1 treated cells stained positive for senescence-associated beta
galactosidase (SA-β-Gal, blue color), a marker for terminally arrested cells. EpCAM transfected cells were predominantly negative and acquired a
more spindle shaped morphology (black arrows). (C) Long term cultures of transfected HMECs in the presence of TGF-β1. EpCAM transfected
cells showed a higher proliferative capacity within the observed time window of 6 days than GFP controls. Bars indicate 25 μm. (D) Cell numbers
were analyzed 1, 3 and 6 days after TGF-β stimulation by counting in a Buerker-Tuerk chamber. EpCAM transfected cells displayed significantly
higher proliferative activities, i.e. higher cell counts after 6 days of growth. (E) Western Blot analysis of differentiation markers for epithelial
mesenchymal transition (vimentin, E-cadherin). (F) EpCAM transfected HMECs show a downregulation of E-cadherin (E-cad) but no significant
upregulation of vimentin (Vim) protein. Stars indicate p values <0.05.
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clusters in the chicken chorioallantoic membrane tissue
revealed morphological and quantitative differences. Cell
clusters of GFP controls were smaller, less frequent and
displayed significantly more lumen formation (Figure 5C,
5D, marked with asterisks). In contrast, EpCAM over-
expressing HMECs formed bigger structures, with more
frequent disseminating cell clusters and therefore, almost
no lumen formation (Figure 5C). Higher cell numbers of
EpCAM overexpressing HMEC grafts were also correlat-
ing with more p63high progenitor cells/high power field
(Figure 5D).EpCAM overexpression enhances cell proliferation in
immortalized MCF-10A cells
Based on our observation that EpCAM overexpression
alone is not enough to reveal its oncogenic features and
that tumorigenesis is a multistep process, we decided to use
the immortalized breast epithelial cell line MCF-10A
(p16INK4a−/−) for additional investigations. MCF10A cells
can be efficiently transduced with adenovirus to overexpress
EpCAM, but loose EpCAM expression faster than HMECs
(Figure 6A). In comparison to HMECs (Figure 2E), MC-
F10A with EpCAM overexpression show an increased cell
proliferation (Figure 6B) and upregulation of c-myc gene
expression (Figure 6C). Changes of c-myc expression could
also be monitored on protein level (Figure 6D/E).
Moreover, MCF10A cell lines were generated by a
lentiviral system to have a stable expression of a non-silen-
cing control (ns/crtl) or an EpCAM specific (E#2) shRNA.
Both cell lines, MCF10A ns/crtl and MCF10A E#2, were
adenovirally transfected to overexpress GFP or EpCAM/
GFP. In comparison to MCF10A ns/crtl cells MCF10A E#2
cells were significantly downregulating EpCAM transcript
levels 24 and 48 h after adenoviral transfection (Figure 6F).
Real time cell proliferation of MCF10A E#2 cells was signifi-
cantly lower than those of MCF10A ns/crtl after adenoviral
EpCAM overexpression (Figure 6G). These data clearly
indicate that EpCAM overexpression can enhance proli-
feration and c-myc levels in immortalized human breast
epithelial cells.Discussion
EpCAM is a widely described tumor-associated antigen,
stem cell and cancer stem cell marker [4,22-24]. Cancer
stem cells with a high EpCAM expression are consid-
ered to be more malignant and more prone to give
metastasis than those with a low expression [24,25].
Although EpCAM overexpression in breast cancer is
correlated with aggressive behavior and decreased over-
all survival of patients [13,25-27], functions and effects
of EpCAM overexpression in normal mammary epithelial
cells, i.e. healthy tissue have not been described so far.
In normal breast epithelia EpCAM has a strict baso-
lateral expression. Among all epithelial cell-types only
myoepithelial cells are EpCAM-negative [28]. Tumor cells
loosing cell-cell contacts and invading host tissue are also
loosing the strict basolateral distribution of EpCAM and
show more cytoplasmic and membranous staining [5,27].
Whether this is mediated by loss of cell polarity or by gen-
eration of translocated EpCAM isoforms is still under in-
vestigation [5,11,29]. Recent studies showed that
glycosylation of EpCAM might affect stability and func-
tion of the protein [30]. Noteworthy, healthy tissue dis-
plays mainly weak expression of basic, not glycosylated
EpCAM protein, whereas in tumor tissue, as well as in
breast cancer cell lines, EpCAM is glycosylated and/or
hyperglycosylated [30]. Differences in glycosylation we
could also observe between highly mitotic cultures and
growth arrested monolayers of transfected human mam-
mary epithelial cells (HMECs).
In vitro cultivated HMECs showed no EpCAM protein
expression, although gene transcripts could be detected
by qPCR in a low abundance. Presumably, these cells
loose expression under artificial in vitro conditions and
loss of normal tissue polarity, since in vivo both basal/
progenitor as well as differentiated luminal cells are
strongly positive for immunoreactive EpCAM. Moreover,
cell-cell adhesions in our HMECs are primarily mediated
by E-cadherin, which has been described to be a counter
player of EpCAM [10,18,31]. Typically, HMEC cultures
age under mitotic stress and induce p16INK4A and/or
p53 [32,33]. Aberrant expression of oncogenes has been










Figure 5 EpCAM overexpression in vivo leads to hyperplastic cell growth without ductal lumen formation. HMECs were transplanted
together with matrigel into the chorioallantoic membrane (CAM) of chicken embryos and cell growth and morphology analyzed after 6 days.
(A) Chicken embryos with HMEC xenografts. White arrows indicate transplants of HMECs in matrigel plugs (B) Fluorescence stereo microscope
picture of a HMEC graft 6 days after in vivo growth. The green clusters (adenoviral GFP) indicate human cell-cell aggregates that growth inside
the CAM (magnification 20×) (C) Immunohistochemical analysis of cross-sections of HMEC grafts in the CAM. Sections were stained with an
antibody specific for human cadherin, thus detecting only human cells. In contrast to GFP transfected controls, EpCAM overexpressing grafts
show bigger glandular structures that lack formation of lumen. (D) Immunohistochemical analysis of p63high progenitor cells. Noteworthy, HMECs
at the glandular base express the progenitor marker p63. EpCAM overexpressing clusters are surrounded by significant bigger clusters of chicken
leukocytes (black arrows). Bars indicate 50 μm, asterisks indicate lumen.
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checkpoint. These check-points of the cellular senes-
cence program protect cells from oncogenic signaling,
prevent immortalization and acquisition of genomic in-
stabilities [34,35] and are very often inactivated in cancer
cells. In comparison to control cells, overexpression of
EpCAM led to inhibition of proliferation and migration
in HMECs. This represents a frequently observedreaction of normal cells to an oncogenic stimulus. How-
ever, in contrast to effects described for oncogenic ras or
the catalytic subunit of the telomerase (TERT) we did
not observe a complete growth arrest mediated by in-
duction of p16INK4A [35,36]. EpCAM transfected
HMECs are inhibited in cell proliferation, but do not
undergo a terminal growth arrest. This might be due to
simultaneous upregulation and accumulation of p53 and
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Figure 6 EpCAM overexpression leads to upregulation of c-myc and increased cell proliferation in immortalized MCF10A human
breast epithelial cells. (A) Flow cytometric analysis of EpCAM expression in adenovirally transfected MCF10A cells. In comparison to GFP
transfected controls, only EpCAM transfected cells show the immunoreactive protein on the cell membrane. (B) Overexpression of EpCAM results
in a significant increase in cell proliferation under serum-reduced conditions. (C) Real time PCR analysis of TP53, p27kip1 and c-myc gene
expression in EpCAM transfected cells. Overexpression of EpCAM upregulated c-myc gene expression. (D) Western Blot analysis of EpCAM
overexpression and upregulation of c-myc protein levels. Tubulin alpha served as internal loading control. (E) Densitometric analysis of c-myc to
tubulin protein ratio. MCF10A cell lines were generated by a lentiviral system to have a stable expression of a non-silencing control (ns/crtl) or an
EpCAM specific (E#2) shRNA. MCF10A ns/crtl and MCF10A E#2 cells were adenovirally transfected to overexpress GFP or EpCAM/GFP. (F) In
comparison to MCF10A ns/crtl cells MCF10A E#2 cells were significantly downregulating EpCAM transcript levels 24 and 48 h after adenoviral
transfection. (G) Real time cell proliferation of MCF10A E#2 cells was significantly lower than those of MCF10A ns/crtl after adenoviral EpCAM
overexpression. Stars indicate p values <0.05.
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EpCAM and p53 has already been reported [37].
EpCAM gene expression is downregulated by p53 and
loss of p53 leads to increased EpCAM expression and a
more invasive phenotype in tumor cells [36,37].
EpCAM did not affect p53 or p27Kip1 gene transcrip-
tion, upregulations were only visible on the protein level.
Thus, EpCAM might induce changes in p53 protein by
affecting posttranscriptional modifications processes orprotein stability [38]. Moreover, p27Kip1 has been shown
to inhibit Rho-A driven cell migration processes [39].
Thus, our HMECs upregulating p27Kip1 after EpCAM
overexpression probably showed an inhibition of cell mi-
gration despite down regulation of the cell-cell adhesion
molecule E-cadherin.
Against our expectations, EpCAM expression alone
did not directly affect transcription of other genes in our
HMEC culture models, although a signaling pathway,
Martowicz et al. Molecular Cancer 2013, 12:56 Page 13 of 15
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ously described in pharyngeal cancer cells [35,36]. In fact,
in HEK293 and FaDu tumor cell lines EpCAM has been
reported to act directly on transcription of c-myc and
cyclins [40,41]. We transfected growth arrested and po-
larized, as well as proliferating HMEC cultures and per-
formed transcriptome analysis 24 h after overexpression
of EpCAM. With this experimental approach we wanted
to identify early genes directly regulated by EpCAM,
before induction of the transcription factor p53 and its
downstream genes. Both attempts gave no evidence that
EpCAM overexpression is directly affecting gene expres-
sion profile of HMECs. Our data indicate that at least in
primary HMECs overexpression of EpCAM, with ab-
sence of other oncogenes or mutations, has no immedi-
ate and direct effect on gene transcription. In fact,
MCF10A, immortalized human epithelial cells having
inactivation of the INK4A (p16) gene locus, respond to
EpCAM overexpression by upregulating c-myc gene
expression. Thus, we assume that other transforming
stimuli have to act together with EpCAM to induce
changes on gene transcription level.
In fact, EpCAM is primarily acting on cell-cell adhesion
proteins such as E-cadherin, claudins, tetraspanins and
CD44 [42]. Changes on their protein levels, localization on
the cell membrane and interactions, might affect intracel-
lular signaling pathways and kinase activities. Indeed, it
has been recently reported that EpCAM affects protein
kinase C signaling and cell migration processes during
gastrulation in xenopus embryos [43].
HMECs are very sensitive to the cytokine TGF-β1 treat-
ment [36]. This cytokine is able to inhibit cell proliferation
and induce EMT differentiation processes in healthy
epithelial cells [44,45]. When HMECs are transfected to
overexpress EpCAM many clones acquire resistance to
TGF-β1 induced growth arrest and display more spindle-
shape phenotype. The underlying mechanism for in-
creased resistance to TGF-β1 mediated growth arrest still
remains to be investigated. Further, our in vivo studies
support the concept of EpCAM overexpression as sup-
portive factor for hyperplastic growth. EpCAM over-
expression together with TFG-β1 and presumably other
mitogenic factors present in Matrigel support hyperplastic
growth and counteract growth arrest and terminal differ-
entiation processes in vivo. We assume that HMECs with
EpCAM overexpression gain longer proliferative capacities
and acquire more resistances to growth inhibition due to
activation of Wnt signaling. This increased stem cell sig-
naling is supported by the observation that EpCAM
overexpressing xenografts display an increased number of
p63+ undifferentiated progenitor cells. This is of particular
interest, since higher amounts of undifferentiated cells in
mammary gland contribute to increased risk to develop
breast cancer [46].Moreover, EpCAM overexpression leads to stronger
innate immune responses in vivo. EpCAM overexpre-
ssing xenografts attracts more neutrophils from host tis-
sue, which would suggest that EpCAM is supporting
migration processes of immune cells as described pre-
viously for dentritic cells [47]. However, further inves-
tigations are necessary to study effects of EpCAM
expression on cancer cells in context of tumor immun-
ology and microenvironment.
Thus, EpCAM overexpression might promote progres-
sion and metastasis of primary tumors. However, further
studies are still needed to identify the underlying mo-
lecular mechanisms responsible for EpCAM overexpre-
ssion in the context of TGF-β/Wnt signaling and breast
cancer development. This background will allow us to
understand the impact of EpCAM overexpression on
transformation of breast epithelial cells and growth of
breast cancer cells.
Conclusions
EpCAM revealed oncogenic features in normal human
breast cells, inducing resistance to TGF-β1-mediated
growth arrest and supporting a cell phenotype with lon-
ger proliferative capacities in vitro. EpCAM overexpre-
ssion resulted in hyperplastic growth and enhanced
innate immune responses in vivo. Thus, we suggest that
EpCAM acts as a prosurvival factor counteracting ter-
minal differentiation processes in normal mammary
glands.
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Additional file 1: Figure S1. Representative immunohistochemical
staining of EpCAM in healthy tissue (A), primary invasive ductal
carcinoma (B) and corresponding lymph node metastasis (C) Note: The
strict basolateral expression of EpCAM in healthy glandular tissue gets
lost in tumor cells in favor to a signal on the entire cell membrane. (D)
Immunofluorescence analysis of EpCAM transfected HMECs. Adenoviral
transfected cells were fixed, permeabilized and stained with an EpCAM
specific antibody (green signal); nuclei were counter-stained with
ToPRO-3 (red signal). Bars indicate 100 μm.
Additional file 2: Figure S2. Flow cytometry analysis of EpCAM
expression on cell membranes of viable HMECs after adenoviral
transfection with EpCAM or GFP. EpCAM high cells were quantified in
direct comparison to GFP transfected controls (A). Apoptosis/necrosis of
HMECs was analyzed 48 h after transfection by staining of Annexin V/
propidium iodide and flow cytometric analysis (B). Relative gene
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http://www.molecular-cancer.com/content/12/1/56expression levels of TP53, p27Kip1 and c-myc were analyzed by RT-qPCR 24
to 72 h after adenoviral transfection and quantified in direct comparison
to GFP transfected control cells (C). Stars indicate p values <0.05.
Additional file 3: Table S1. Affymetrix chip analysis of HMECs (n = 3)
adenovirally transfected to overexpress EpCAM. Gene expression in
EpCAM transfected cells was quantified relative to respective control
transfections with GFP. Mean ± standard deviation (SD).
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